Next Article in Journal
Developments and Challenges for mAb-Based Therapeutics
Previous Article in Journal
In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells
Previous Article in Special Issue
Characterization of a Phospho-Specific Antibody to the Fcε Receptor γ Chain, Reveals Differences in the Regulation of Syk and Akt Phosphorylation
Open AccessReview

Molecular Engineering of Therapeutic Cytokines

Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia
*
Author to whom correspondence should be addressed.
Antibodies 2013, 2(3), 426-451; https://doi.org/10.3390/antib2030426
Received: 9 May 2013 / Revised: 13 June 2013 / Accepted: 13 June 2013 / Published: 3 July 2013
(This article belongs to the Special Issue Cytokine Growth Factor Antibodies in Immunotherapy)
Over the past three decades, a large body of work has been directed at the development of therapeutic cytokines. Despite their central role in immune modulation, only a handful of cytokine therapeutics has achieved regulatory approval. One of the major challenges associated with the therapeutic use of cytokines relates to their short serum half-life and low bioavailability. High doses are required to overcome these problems, which often result in dose-limiting toxicities. Consequently, most cytokines require protein engineering approaches to reduce toxicity and increase half-life. For this purpose, PEGylation, fusion proteins, antibody complexes and mutagenesis have been utilized. Here, we summarize past, recent and emerging strategies in this area. View Full-Text
Keywords: immunotherapy; cytokines; protein engineering; immunocytokines; fusion proteins immunotherapy; cytokines; protein engineering; immunocytokines; fusion proteins
Show Figures

Figure 1

MDPI and ACS Style

Vazquez-Lombardi, R.; Roome, B.; Christ, D. Molecular Engineering of Therapeutic Cytokines. Antibodies 2013, 2, 426-451. https://doi.org/10.3390/antib2030426

AMA Style

Vazquez-Lombardi R, Roome B, Christ D. Molecular Engineering of Therapeutic Cytokines. Antibodies. 2013; 2(3):426-451. https://doi.org/10.3390/antib2030426

Chicago/Turabian Style

Vazquez-Lombardi, Rodrigo; Roome, Brendan; Christ, Daniel. 2013. "Molecular Engineering of Therapeutic Cytokines" Antibodies 2, no. 3: 426-451. https://doi.org/10.3390/antib2030426

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop